In Vitro Study of Combined Application of Bevacizumab and 5-Fluorouracil or Bevacizumab and Mitomycin C to Inhibit Scar Formation in Glaucoma Filtration Surgery

Table 3

Cell viability of human Tenon’s fibroblasts (HTFs) after treatment with bevacizumab (BVZ), 5-fluorouracil (5-Fu), BVZ/5-Fu, mitomycin C (MMC), and BVZ/MMC.

Medicine and concentration (mg/ml)		Absorbance at 570 nm (ratio, compared to PBS)	Medicine and concentration (mg/ml)		Absorbance at 570 nm (ratio, compared to PBS)
BVZ	0.025	1.0596 ± 0.0307
	0.25	0.7871 ± 0.1008
	2.5	0.2376 ± 0.0084
5-Fu	0.05	1.0161 ± 0.0335	BVZ0.25/5-Fu	0.05	0.6626 ± 0.1499
	0.5	0.8961 ± 0.0284		0.5	0.7962 ± 0.0365
	5	0.8417 ± 0.0258		5	0.7426 ± 0.0270
MMC	0.00002	1.0994 ± 0.0461	BVZ0.25/MMC	0.00002	0.4837 ± 0.1337
	0.0002	1.0390 ± 0.0250		0.0002	0.5255 ± 0.0942
	0.002	0.9512 ± 0.0266		0.002	0.4980 ± 0.1015